ERASErasca, Inc.

Nasdaq erasca.com


$ 1.98 $ 0.01 (0.51 %)    

Friday, 17-May-2024 11:29:25 EDT
QQQ $ 452.13 $ -0.59 (-0.13 %)
DIA $ 398.72 $ -0.40 (-0.1 %)
SPY $ 528.72 $ -0.21 (-0.04 %)
TLT $ 91.60 $ -0.02 (-0.02 %)
GLD $ 222.72 $ 0.51 (0.23 %)
$ 1.85
$ 1.97
$ 1.98 x 200
$ 2.00 x 4,600
$ 1.85 - $ 2.05
$ 1.51 - $ 3.38
410,833
na
279.65M
$ 1.73
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-24-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-26-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-erasca-prices-underwritten-offering-of-86486486-common-stock-at-185share

Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable sec...

 reported-earlier-erasca-entered-into-exclusive-license-agreements-for-two-preclinical-ras-programs

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class prof...

 erasca-plans-to-deprioritize-eras-007-eras-801-programs-to-discontinue-its-existing-internal-eras-4-pan-kras-program

The Company will deprioritize the ERAS-007 program as the Company believes the clinical efficacy data from the HERKULES-3 clini...

 erasca-reveals-reduction-in-workforce-by-18-in-connection-with-strategic-reprioritization-primarily-affecting-employees-working-in-drug-discovery-functions-or-on-deprioritized-programs---filing

https://www.sec.gov/ix?doc=/Archives/edgar/data/1761918/000119312524140591/d832290d8k.htm

 hc-wainwright--co-reiterates-buy-on-erasca-maintains-8-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

 erasca-q1-eps-023-misses-022-estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4...

 goldman-sachs-maintains-buy-on-erasca-raises-price-target-to-7

Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price target from $6 to $7.

 hc-wainwright--co-reiterates-buy-on-erasca-maintains-8-price-target

HC Wainwright & Co. analyst Andres Maldonado reiterates Erasca (NASDAQ:ERAS) with a Buy and maintains $8 price target.

 reported-earlier-erasca-announced-45m-oversubscribed-private-placement-financing

Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, d...

 erasca-q4-eps-020-beats-021-estimate

Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.21) by 4.7...

 capital-one-initiates-coverage-on-erasca-with-overweight-rating-announces-price-target-of-8

Capital One analyst Naureen Quibria initiates coverage on Erasca (NASDAQ:ERAS) with a Overweight rating and announces Price ...

Core News & Articles

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initia...

 b-of-a-securities-downgrades-erasca-to-neutral-lowers-price-target-to-6

B of A Securities analyst Alec Stranahan downgrades Erasca (NASDAQ:ERAS) from Buy to Neutral and lowers the price target fro...

 riskon-international-and-3-other-stocks-under-2-insiders-are-buying

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence ...

 17m-bet-on-erasca-check-out-these-4-penny-stocks-insiders-are-aggressively-buying

The Dow Jones closed lower by around 70 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...

 mizuho-maintains-buy-on-erasca-lowers-price-target-to-7

Mizuho analyst Mara Goldstein maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $8 to $7.

 why-senestech-shares-are-trading-lower-by-around-50-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5....

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION